EUVIMEDEUVIMED entdecken
Crossref

Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases

Tanya Lynn Gustafson, Barbara Biller

Journal of the American Animal Hospital Association · 2019 · 55 (5) · 243-248

DOI: 10.5326/jaaha-ms-6905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Animal Hospital Association, 2019. Verfasst von Tanya Lynn Gustafson und 1 weiteren Autor:innen. Beteiligte Einrichtung: From Animal Cancer Care Center, Fort Lauderdale, Florida (T.L.G.); and Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado …. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transitional cell carcinoma (TCC) is a locally aggressive tumor in dogs with low-to-moderate responses to traditional chemotherapeutic agents. Toceranib (TOC) phosphate represents a novel agent for the treatment of canine TCC. Thirty-seven dogs were identified who had received TOC for bladder tumor treatment. The TOC was generally well tolerated, although 56% of dogs had progression of azotemia while receiving TOC. A partial response to TOC was observed in 6.7% of dogs, and 80% of dogs had stable disease for a median duration of 128.5 days. Median time to progression was 96 days, and median survival time after the start of TOC was 149 days. There were no significant variables influencing time to progression or survival time in this group of dogs. This retrospective study suggests that TOC may be useful for the treatment of TCC. However, careful monitoring of renal function is recommended in patients with bladder tumors receiving TOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsAntineoplastic AgentsCarcinoma, Transitional CellDog DiseasesDogsFemaleIndolesMalePyrrolesRetrospective StudiesUrinary Bladder Neoplasms

Substanzen

Antineoplastic AgentsIndolesPyrrolestoceranib phosphate

Autor:innen und Institutionen

  • From Animal Cancer Care Center, Fort Lauderdale, Florida (T.L.G.); and Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado (B.B.).

Zitieren

APA

Gustafson, T. L., & Biller, B. (2019). Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases. Journal of the American Animal Hospital Association, 55(5), 243-248. https://doi.org/10.5326/jaaha-ms-6905

Vancouver

Gustafson TL, Biller B. Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases. Journal of the American Animal Hospital Association. 2019;55(5):243-248. doi:10.5326/jaaha-ms-6905

BibTeX
@article{Gustafson2019,
  author = {Gustafson, Tanya Lynn and Biller, Barbara},
  title = {Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases},
  journal = {Journal of the American Animal Hospital Association},
  year = {2019},
  volume = {55},
  number = {5},
  pages = {243--248},
  doi = {10.5326/jaaha-ms-6905}
}
Kostenlos starten →